Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05833542 · ClinicalTrials.gov registry record · NA
Assessing Perceptions and Preferences Around Long-acting Injectables (APPLI)
A NA study, sponsored by City University of New York.
- Completed
- Registry status
- NA
- Development phase
- 243
- Enrollment target
NCT05833542 is a NA study that has completed, run by City University of New York. The registered enrollment target is 243 participants.
The verdict
NCT05833542, a NA study, has completed, sponsored by City University of New York.
- COMPLETED
- Registry status
- NA
- Development phase
- 243 participants
- Enrollment target
Study Summary
The Ryan White HIV/AIDS Program is an essential platform for reducing health disparities among people with HIV and scaling up evidence-based strategies to strengthen the HIV care continuum. The investigators propose an implementation-science study based in New York Ryan White Part A programs, to inform the delivery of long-acting injectable antiretroviral therapy and related supportive services to low-income, largely Black and Latino/a people with HIV who have struggled with daily oral antiretroviral therapy adherence. As a major biomedical advance de-necessitating adherence to daily dosing, long-acting injectable antiretroviral therapy could greatly increase opportunities for health, survival and transmission prevention, particularly in populations confronting complex barriers to viral load suppression. However, optimizing the public health impact of long-acting injectable antiretroviral therapy will require implementation science to assess perceptions and preferences around long-acting injectable versus daily oral regimens, identify support services and delivery mechanisms suited to promoting long-acting injectable uptake and engagement, and address the role of provider beliefs as to which patients should be offered long-acting injectable options. In the absence of this groundwork, long-acting injectable antiretroviral therapy may primarily reach those who are already relatively advantaged, and even exacerbate HIV disparities.
Interventions
- BEHAVIORAL Health education materials
- BEHAVIORAL Patient-provider decision tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2024-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05833542
The ClinicalTrials.gov registry entry for NCT05833542 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City University of New York, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Health education materials is the first listed.
NCT05833542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05833542 about?
NCT05833542 is a clinical study titled "Assessing Perceptions and Preferences Around Long-acting Injectables (APPLI)". The Ryan White HIV/AIDS Program is an essential platform for reducing health disparities among people with HIV and scaling up evidence-based strategies to strengthen the HIV care continuum. The investigators propose an implementation-science study based in New York Ryan White Part A programs, to inf...
What is the current status of trial NCT05833542?
This trial is currently completed. It is a NA study. The enrollment target is 243 participants. The study started on 2023-05-03. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT05833542?
The interventions under investigation include: Health education materials (BEHAVIORAL), Patient-provider decision tool (BEHAVIORAL).
Who is sponsoring clinical trial NCT05833542?
This trial is sponsored by City University of New York, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.